Fletikumab

Drug Profile

Fletikumab

Alternative Names: Anti-IL-20; NN-8226; NNC0109-0012

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 20 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 02 Sep 2014 Discontinued - Phase-II for Rheumatoid arthritis in USA, Czech Republic, Argentina, Brazil, Mexico, Poland, Romania, Spain, Germany, Belgium, Hungary, United Kingdom, France and Italy (SC)
  • 07 Aug 2014 Efficacy data from a phase IIb trial in Rheumatoid arthritis released by Novo Nordisk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top